Andreas Engert
University Hospital of Cologne
Department of Internal Medicine I
Germany
Name/email consistency: high
- Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Král, Z., Fuchs, M., Hallek, M., Kanz, L., Döhner, H., Dörken, B., Engel, N., Topp, M., Klutmann, S., Amthauer, H., Bockisch, A., Kluge, R., Kratochwil, C., Schober, O., Greil, R., Andreesen, R., Kneba, M., Pfreundschuh, M., Stein, H., Eich, H.T., Müller, R.P., Dietlein, M., Borchmann, P., Diehl, V. Lancet (2012)
- Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. von Tresckow, B., Plütschow, A., Fuchs, M., Klimm, B., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M.S., Meissner, J., Zijlstra, J.M., Soekler, M., Stein, H., Eich, H.T., Mueller, R.P., Diehl, V., Borchmann, P., Engert, A. J. Clin. Oncol. (2012)
- Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group. Borchmann, P., Haverkamp, H., Diehl, V., Cerny, T., Markova, J., Ho, A.D., Eich, H.T., Mueller-Hermelink, H.K., Kanz, L., Greil, R., Rank, A., Paulus, U., Smardova, L., Huber, C., Dörken, B., Nerl, C., Krause, S.W., Mueller, R.P., Fuchs, M., Engert, A. J. Clin. Oncol. (2011)
- Lymphocyte-Depleted Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. Klimm, B., Franklin, J., Stein, H., Eichenauer, D.A., Haverkamp, H., Diehl, V., Fuchs, M., Borchmann, P., Engert, A. J. Clin. Oncol. (2011)
- Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. Engert, A., Plütschow, A., Eich, H.T., Lohri, A., Dörken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K.C., Wilhelm, M., Debus, J., Eble, M.J., Sökler, M., Ho, A., Rank, A., Ganser, A., Trümper, L., Bokemeyer, C., Kirchner, H., Schubert, J., Král, Z., Fuchs, M., Müller-Hermelink, H.K., Müller, R.P., Diehl, V. N. Engl. J. Med. (2010)
- Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. Engert, A., Josting, A., Haverkamp, H., Villalobos, M., Lohri, A., Sökler, M., Zijlstra, J., Sturm, I., Topp, M.S., Rank, A., Zenz, T., Vogelhuber, M., Nogova, L., Borchmann, P., Fuchs, M., Flechtner, H.H., Diehl, V. J. Clin. Oncol. (2010)
- Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dörken, B., Ludwig, W.D., Koch, P., Hänel, M., Pfreundschuh, M., Wilhelm, M., Trümper, L., Aulitzky, W.E., Bentz, M., Rummel, M., Sezer, O., Müller-Hermelink, H.K., Hasenclever, D., Löffler, M. J. Clin. Oncol. (2009)
- Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Engert, A., del Giglio, A., Bias, P., Lubenau, H., Gatzemeier, U., Heigener, D. Onkologie (2009)
- XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Engert, A., Griskevicius, L., Zyuzgin, Y., Lubenau, H., del Giglio, A. Leuk. Lymphoma (2009)
- Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Engert, A., Franklin, J., Eich, H.T., Brillant, C., Sehlen, S., Cartoni, C., Herrmann, R., Pfreundschuh, M., Sieber, M., Tesch, H., Franke, A., Koch, P., de Wit, M., Paulus, U., Hasenclever, D., Loeffler, M., Müller, R.P., Müller-Hermelink, H.K., Dühmke, E., Diehl, V. J. Clin. Oncol. (2007)
- Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. Engert, A., Bredenfeld, H., Döhner, H., Ho, A.D., Schmitz, N., Berger, D., Bacon, P., Skacel, T., Easton, V., Diehl, V. Haematologica (2006)
- Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Dühmke, E., Müller-Hermelink, K., Diehl, V. J. Clin. Oncol. (2005)
- Recombinant human erythropoietin in oncology: current status and further developments. Engert, A. Ann. Oncol. (2005)
- Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Schnell, R., Borchmann, P., Staak, J.O., Schindler, J., Ghetie, V., Vitetta, E.S., Engert, A. Ann. Oncol. (2003)
- Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Bohlius, J., Reiser, M., Schwarzer, G., Engert, A. Br. J. Haematol. (2003)
- The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. Engert, A., Sausville, E.A., Vitetta, E. Curr. Top. Microbiol. Immunol. (1998)